Abstract | STUDY QUESTION: SUMMARY ANSWER: WHAT IS KNOWN ALREADY: The LNG-IUS and oral progestogens are both equally used to treat women with EH. There is uncertainty about whether the LNG-IUS is a better therapy for EH. STUDY DESIGN, SIZE, DURATION: This comparative cohort study included 344 women recruited from August 1998 until December 2010. PARTICIPANTS/MATERIALS, SETTING, METHODS: Women with complex non-atypical or atypical EH were treated with the LNG-IUS (n = 250) or oral progestogens (n = 94) in a tertiary referral hospital. We evaluated the proportion of women who regressed or underwent hysterectomy after treatment with the LNG-IUS compared with oral progestogens by logistic regression adjusting for confounding. The time from diagnosis to regression was explored through a survival analysis. MAIN RESULTS AND THE ROLE OF CHANCE: The follow-up rate was 95.3%. The mean length of follow-up in the two groups was 66.9 ± SD 35.1 months for the LNG-IUS and 87.2 ± SD 45.5 months for the oral progestogen group. Regression of hyperplasia was achieved in 94.8% (237/250) of patients with the LNG-IUS compared with 84.0% (79/94) of patients treated with oral progestogens (adjusted odds ratio (OR) = 3.04, 95% CI 1.36-6.79, P = 0.001). Hysterectomy rates were lower in the LNG-IUS group during follow-up (22.1, 55/250 versus 37.2%, 35/94, adjusted OR = 0.48, 95% CI 0.28-0.81, P < 0.004). Endometrial cancer was diagnosed in 8 (33%) women who had hysterectomy because of a failure to regress to normal histology during follow-up (n = 24). LIMITATIONS, REASONS FOR CAUTION: The observational design cannot exclude residual confounding from unmeasured variables. WIDER IMPLICATIONS OF THE FINDINGS:
|
Authors | Ioannis D Gallos, Preeti Krishan, Manjeet Shehmar, Raji Ganesan, Janesh K Gupta |
Journal | Human reproduction (Oxford, England)
(Hum Reprod)
Vol. 28
Issue 11
Pg. 2966-71
(Nov 2013)
ISSN: 1460-2350 [Electronic] England |
PMID | 23975691
(Publication Type: Comparative Study, Journal Article, Observational Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Contraceptive Agents, Female
- Progestins
- Levonorgestrel
|
Topics |
- Administration, Oral
- Adult
- Cohort Studies
- Contraceptive Agents, Female
(administration & dosage, adverse effects, therapeutic use)
- Endometrial Hyperplasia
(drug therapy, pathology)
- Female
- Humans
- Hysterectomy
- Intrauterine Devices
(adverse effects)
- Levonorgestrel
(administration & dosage, adverse effects, therapeutic use)
- Logistic Models
- Middle Aged
- Odds Ratio
- Progestins
(administration & dosage, adverse effects, therapeutic use)
|